# Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)

> **NCT01672853** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 235 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis (PSC)

## Interventions

- **BIOLOGICAL:** Simtuzumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01672853
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-04
- **Primary completion:** 2016-08-08
- **Final completion:** 2016-08-24
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2019-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01672853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01672853, "Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01672853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*